Tumor necrosis factor-alpha inhibitor use for treatment of refractory cardiac sarcoidosis in a patient with left ventricular assist device: Adalimumab use in refractory sarcoidosis in a patient with left ventricular assist device. 

 -  2020 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1053-2498 
<br/><br/><label>Standard No.: </label>10.1016/j.healun.2020.08.001 [doi] S1053-2498(20)31690-9 [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Adalimumab/tu [Therapeutic Use]<br/>*Cardiomyopathies/th [Therapy]<br/>*Heart Failure/th [Therapy]<br/>*Heart-Assist Devices<br/>*Sarcoidosis/th [Therapy]<br/>*Tumor Necrosis Factor-alpha/ai [Antagonists & Inhibitors]<br/>Adult<br/>Anti-Inflammatory Agents/tu [Therapeutic Use]<br/>Cardiomyopathies/co [Complications]<br/>Cardiomyopathies/di [Diagnosis]<br/>Female<br/>Heart Failure/di [Diagnosis]<br/>Heart Failure/et [Etiology]<br/>Humans<br/>Positron-Emission Tomography<br/>Sarcoidosis/co [Complications]<br/>Sarcoidosis/di [Diagnosis]<br/>Treatment Outcome
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Heart & Vascular Institute
<br/><br/><label>Index Terms--Function: </label><br/>Letter